SCHEMBL16617938

SCHEMBL16617938

COC(=O)[C@@H]1CCCC[C@H]1c1oc(C(F)(F)C(F)(F)F)nc1-c1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.41
SLC6A4 P31645 5/20 0.41
CTSK P43235 1/20 0.34
RAB9A P51151 2/20 0.34
CNR1 P21554 1/20 0.34
NPC1 O15118 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC6A3 Q01959 5/20 0.32
CNR2 P34972 1/20 0.32
ACKR3 P25106 1/20 0.32
HDAC3 O15379 2/20 0.32
HDAC1 Q13547 2/20 0.32
HDAC2 Q92769 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
CPT2 P23786 1/20 0.31
CPT1A P50416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16617912 0.88 CTSK (0.34) CTSKCNR1HDAC3HDAC1HDAC2
SCHEMBL16618090 0.88 CTSK (0.34) CTSKCNR1HDAC3HDAC1HDAC2
SCHEMBL16617294 0.81 CTSK (0.48) SLC6A2SLC6A4CTSKCNR1ACKR3
SCHEMBL16617295 0.81 CTSK (0.48) SLC6A2SLC6A4CTSKCNR1ACKR3
SCHEMBL16638066 0.81 CTSK (0.48) SLC6A2SLC6A4CTSKCNR1ACKR3
SCHEMBL16617671 0.81 CTSK (0.54) CTSK
SCHEMBL16617323 0.80 ACKR3 (0.46) SLC6A2SLC6A4CTSKRAB9ACNR1
SCHEMBL16617324 0.80 ACKR3 (0.46) SLC6A2SLC6A4CTSKRAB9ACNR1
SCHEMBL16617754 0.77 CTSK (0.38) SLC6A2SLC6A4CTSKRAB9ACNR1
SCHEMBL16617752 0.77 CTSK (0.38) SLC6A2SLC6A4CTSKRAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CTSK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.